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Background: The prognostic signiﬁcance of sarcopenia and sarcopenic obesity (SO) among older people
remains controversial. The main aim of this study was to evaluate the mortality risk of sarcopenia and SO
among men aged 75 years and older in Taiwan.
Methods: This prospective cohort study recruited all residents of the Banciao Veterans Home, a veterans
retirement community in Taipei City in northern Taiwan. For all study participants, the demographic
proﬁle, comorbid medical conditions, biochemical markers, handgrip strength and gait speed, sarcope-
nia, SO, and all-cause mortality were collected during a 3-year follow-up period.
Results: In the study, 680 residents participated. The prevalence of sarcopenia and SO was 60.3% and
19.7%, respectively. During the study period, 140 (20.6%) deaths were identiﬁed. The diseased individuals
were older, more prone to having diabetes mellitus and sarcopenia, had lower serum levels of total
cholesterol and triglycerides, but had no difference in SO. Comparisons between different statuses of SO
showed that age; diabetes mellitus; metabolic syndrome; body mass index; waist circumference;
handgrip strength; gait speed; systolic blood pressure; fasting plasma glucose; serum levels of total
cholesterol, triglyceride, high-density lipoprotein; and mortality were all signiﬁcantly different between
the groups. Sarcopenia [odds ratio (OR), 2.64; 95% conﬁdence interval (C.I.), 1.687e4.135; p < 0.001],
diabetes mellitus (OR, 1.70; 95% CI, 1.083e2.267; p ¼ 0.021) were independent risk factors for mortality;
whereas the serum level of triglyceride was protective (OR, 0.99; 95% CI, 0.989e0.997; p ¼ 0.001). The
Cox proportional hazard model conﬁrmed that sarcopenia was signiﬁcantly associated with mortality
with or without obesity.
Conclusion: The mortality risk of sarcopenia signiﬁcantly outweighed the survival beneﬁts of obesity in
old age. The unfavorable impact of SO may eventually result from sarcopenia, but not obesity.
Copyright  2014, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license.1. Introduction
Sarcopenia, the age-related loss of skeletal muscle and decline in
muscle strength,1,2 is reportedly associated with a number of
adverse clinical outcomes such as physical disability, falls, fractures,
frailty, extended hospitalization, infectious and noninfectious
complications at hospital admissions, and all-cause mortality.3e9
However, sarcopenia may sometimes coexist with an increase in
fat mass [i.e., sarcopenic obesity (SO)], which suggests that theGerontology, Taipei Veterans
ad, Taipei 11217, Taiwan.
).
Clinical Gerontology & Geriatrics.conﬂuence of the two individual body composition phenotypes
may potentiate the mutually adverse health impacts,10,11 and that
the prevalence of sarcopenia signiﬁcantly increases with age.12e14
Sarcopenic obesity has attracted extensive research attention;
however, a standardized diagnostic strategy is still lacking. Despite
the lack of standardized diagnostic strategy, various health risks of
SO have been demonstrated such as higher cardiovascular dis-
ease,15 lower physical function and cardiopulmonary ﬁtness,16
physical disability,17 frailty and poorer quality of life,6,18 longer
hospitalization,19 and higher mortality of patients with end-stage
renal disease and tumor.20,21
Whether the abovementioned health impacts result from SO or
sarcopenia per se nonetheless remains controversial. Among allPublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
 
Table 1
Demographic characteristics of older men aged 75 years or older living in the
Banciao Veterans Home in Taipei, Taiwan.
Overall (N ¼ 680)
Age (y) 82.5  4.7
Height (cm) 162.8  6.4
Weight (kg) 62.6  9.8
Body mass index (kg/m2) 23.7  3.3
Hypertension 56.2
Diabetes mellitus 22.2
Metabolic syndrome 31.6
Current smoker 34.3
Alcohol drinker 20.3
Physically active 67.0
Handgrip strength (kg) 18.9  9.6
Gait speed (m/s) 0.88  0.34
Sarcopenic obesity status
Sarcopenia (), central obesity ()
Sarcopenia (), central obesity (þ)
Sarcopenia (þ), central obesity ()
Sarcopenia (þ), central obesity (þ)
24.7
15.0
40.6
19.7
All-cause mortality 20.6
Cancer 2.9
Cardiovascular disease 5.4
Infectious disease 9.1
Other 3.1
Data are presented as mean  SD or %.
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tality in otherwise healthy older adults remains unclear because
the effects of obesity and sarcopenia on the mortality of the elderly
seem to develop in opposite directions. Evidence suggests that the
relationship between the body mass index (BMI) and mortality in
the elderly is a U-shaped curve, whereas the risk of mortality rises
only at extreme BMI values over 35e40 kg/m2.22,23 Jassen5 and
colleagues moreover report that increased BMI was protective
against mortality for people aged 65 years and older, after con-
trolling for waist circumference (WC). However, increased WC was
associated with mortality when controlling for BMI, which implied
that BMI may represent lean body mass for individuals with an
equivalent WC, and WC reﬂects fat mass for individuals with an
equal BMI.24 This discovery indicates that adiposity may still play
an unfavorable role in mortality among older people. The double
health burden model of SO concerning the health of older people
seems reasonable; however, rarely do studies really examine the
combined effect of obesity and muscle mass or strength on mor-
tality in the elderly, and data from The Third National Health and
Nutrition Examination Survey clearly showed that SO was not
associatedwith poor functioning.25,26 It has been hypothesized that
obesity alone in old age may protect against mortality, but the risk
of mortality may outweigh the protective effect if obesity is com-
bined with low muscle strength.27 Therefore, the main purpose of
this study was to evaluate the mortality impact of SO among Chi-
nese men aged 75 years and older in Taiwan.2. Methods
2.1. Participants
This study invited all people to participate who were aged
75 years or older living in the Banciao Veterans Home (Taipei,
Taiwan), a veterans retirement community that is similar to assis-
ted living residences in the United States. Most Banciao Veterans
Home residents were physically ﬁt and cognitively intact.28e32
From March 2008 through July 2008, all residents who consented
to participate in this study were enrolled, and then followed for
3 years. For all participants, the survival status was determined
through personal interviews conducted by research nurses or ob-
tained from the Veterans AffairsWelfare Registry, which is linked to
the National Death Registry (Taipei, Taiwan) in a real-time manner.
This study was approved by the Institutional Review Board of the
National Yang Ming University (Taipei, Taiwan).2.2. Data collection
For all participants, demographic proﬁle, medical history,
smoking, physical activities, and alcohol consumption were
collected by a self-administrated questionnaire. Health behaviors
were also collected such as smoking, habitual alcohol use, and
physical activities.31 Research nurses performed anthropometric
measurements of all participants, including sitting blood pressure,
body height and weight, WC, handgrip strength, and a 6-m walk.
Handgrip strength was measured by a digital dynamometer
(T.K.K.5401; Takei Scientiﬁc Instruments Co., Ltd., Niigata, Japan)
when patients were placed in an upright position with the un-
supported, dominant arm parallel to the body. The highest value of
three repeated trials was recorded for further data analysis.
Moreover, the usual gait speed was measured by a 6-m walk.32 For
each participant, venous blood sampling was performed after a 10-
hour overnight fast. Serum levels of total cholesterol (TC), low-
density lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), serum triglyceride (TG), and fasting bloodglucose (FPG) were measured by an automated clinical analyzers
(XE-2100; Sysmex, Kobe, Japan and ADVIA 1800; Siemens).
2.3. Deﬁnition of metabolic syndrome and sarcopenic obesity
Metabolic syndrome (MS) was deﬁned by the National Choles-
terol Education Program Adult Treatment Panel III Guideline
(ATPIII) criteria, which was modiﬁed by the International Diabetes
Federation for Chinese males. The diagnostic criteria included: (1)
fasting glucose level of 100 mg/dL or greater or drug treatment for
an elevated glucose level; (2) serum triglyceride level of 150 mg/dL
or greater or drug treatment for an elevated triglyceride level; (3)
HDL-C level less than 40 mg/dL or drug treatment for a reduced
HDL-C level; (4) systolic blood pressure 130 mmHg or greater or a
diastolic blood pressure of 85 mmHg or greater, or drug treatment
for hypertension; and (5) waist circumference of 90 cm or greater
or a BMI of 25 kg/m2 or greater.
In this study, SO was deﬁned when patients concomitantly
demonstrated central obesity (WC of 90 cm or greater) and sar-
copenia (surrogated by low handgrip strength).27,33 BecauseWC is
reportedly more associated with adverse outcomes than with BMI
in this age group,24 we selected WC rather than BMI to surrogate
adiposity in this study. However, the cutoff for handgrip strength
was modiﬁed in accordance with data from a Taiwanese norm.34
Wu et al34 report that the handgrip strength was approximately
25% lower in men aged 65 years and older than in Caucasians of
the same age and sex; therefore, the cutoff for low handgrip
strength in this study was deﬁned as less than 22.5 kg, according
to the European consensus33 with modiﬁcation for ethnic con-
siderations. All patients were categorized into four groups, ac-
cording to their SO status: (1) sarcopenia-negative and central
obesity-negative; (2) sarcopenia-negative and central obesity-
positive; (3) sarcopenia-positive and central obesity-negative;
and (4) sarcopenia-positive and central obesity-positive (i.e., SO
by our deﬁnition).
2.4. Data analysis
In this study, continuous variables were expressed as the mean
and the standard deviation, and categorical variables were
Table 2
Comparison of the characteristics between older people aged 75 years old who died
and people who survived during the follow-up period.
Mortality (þ)
(N ¼ 140)
Mortality ()
(N ¼ 540)
p
Age (y) 83.4  5.1 82.3  4.5 0.011
Hypertension 52.1 57.2 0.280
Diabetes mellitus 28.6 20.6 0.042
Smoking 39.3 33.1 0.323
Alcohol drinking 12.1 22.2 0.054
Exercise 63.6 67.8 0.476
Body mass index (kg/m2) 23.4  3.4 23.8  3.3 0.201
Waist circumference (cm) 85.7  9.1 86.5  9.3 0.406
Systolic blood pressure (mmHg) 135.9  21.5 138.3  22.0 0.246
Diastolic blood pressure (mmHg) 71.9  14.8 70.8  13.0 0.395
Fasting plasma glucose (mg/dL) 106.3  35.4 106.3  30.7 0.993
Serum total cholesterol (mg/dL) 168.5  34.6 180.2  36.7 0.001
Serum triglyceride (mg/dL) 104.2  45.1 129.2  75.7 <0.001
Serum HDL-C (mg/dL) 59.6  14.3 59.0  15.6 0.667
Handgrip strength (Kg) 16.3  8.8 19.6  9.6 <0.001
Gait speed (m/s) 0.74  0.30 0.91  0.34 <0.001
Sarcopenia 78.6 55.6 <0.001
Sarcopenic obesity 23.9 19.8 0.293
Data are presented as mean  SD or %.
HDL-C ¼ high-density lipoprotein cholesterol.
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tween continuous variables were performed by using the Student t
test. Comparisons between categorical variables were performed
with the Chi-square test, when appropriate. One-way analysis of
variance (ANOVA) was used to compare variables between the
different statuses of SO and the Bonferroni test was used for post
hoc analysis. Multivariate logistic regressionwas used to determine
the independent risk factors for mortality by inputting all statisti-
cally signiﬁcant factors in the univariate analysis. Cox proportional
hazards regression analysis was used to compare the mortality risk
of patients with different statuses of SO. All statistical analyses were
performed by commercial software (SPSS version 17.0; SPSS Inc.,
Chicago, IL, USA). For all tests, p< 0.05 (two-tailed) was statistically
signiﬁcant.3. Results
The study enrolled 680 menwith a mean age of 82.5 4.7 years
(range, 75e102 years). Table 1 summarizes the demographic
characteristics. The overall prevalence of sarcopenia and SO was
60.3% and 19.7%, respectively. At the end of the follow-up period,Table 3
Comparison of the demographic characteristics between older people aged 75 years and
Sarcopenia ()
Central obesity ()
(N ¼ 168)
Sarcopenia ()
Central obesity (þ
(N ¼ 102)
Age (y) 82.0  4.5 81.5  4.3
Hypertension 52.3 63.7
Diabetes mellitus 14.3 28.4
Metabolic syndrome 12.5 76.5
Body mass index (kg/m2) 22.5  2.5 26.5  2.8
Waist circumference (cm) 81.6  5.9 96.7  6.2
Handgrip strength (cm) 27.0  3.4 28.2  3.8
Gait speed (m/s) 1.0  0.3 1.0  0.3
Systolic blood pressure (mmHg) 140.3  23.1 140.1  19.6
Diastolic blood pressure (mmHg) 70.3  14.1 72.2  11.4
Fasting plasma glucose (mg/dL) 102.7  22.7 115.7  42.0
Serum total cholesterol (mg/dL) 182.8  37.5 183.1  37.0
Serum triglyceride (mg/dL) 118.6  72.9 143.4  75.7
Serum HDL-C (mg/dL) 61.7  17.1 56.2  14.5
Mortality 8.9 14.7
Data are presented as mean  SD or %.
HDL-C ¼ high-density lipoprotein cholesterol.140 (20.6%) deaths were identiﬁed; 62 (9.1%) deaths were caused
by infectious diseases; 37 (5.4%) deaths, by cardiovascular disease;
20 (2.9%) deaths, by cancer; and 21 (3.1%) deaths, by other causes
such as accidents or injuries. Table 2 compared the clinical char-
acteristics between the diseased patients and the surviving pa-
tients. The comparison revealed that that the diseased patients
were older, more prone to having diabetes mellitus and sarcopenia,
had lower serum levels of TC and TG, whereas sarcopenic obesity
was not signiﬁcantly different between the groups.
Table 3 summarizes the comparison between participants with
different statuses of SO. The comparison showed that age, diabetes
mellitus, MS, BMI, WC, handgrip strength, gait speed, systolic blood
pressure, FPG, serum levels of TC, TG, HDL-C, and mortality were all
signiﬁcantly different between the groups. In particular, the mor-
tality rate was highest in the sarcopenia-positive and central
obesity-negative groupsdeven more so than in the SO group
(28.3% vs. 23.9%, p ¼ 0.042). Cardiometabolic characteristics were
poorer in the SO group; however, the mortality risk was highest
among sarcopenia-positive and central obesity-negative patients
(Table 3).
Multivariate logistic regression showed that sarcopenia
(OR ¼ 2.64; 95% C.I., 1.687e4.135; p < 0.001) and diabetes mellitus
(OR¼ 1.70; 95% C.I., 1.083e2.267; p¼ 0.021) were independent risk
factors for mortality; but the serum level of TG was a protective
factor (OR ¼ 0.99; 95% C.I, 0.989e0.997; p ¼ 0.001; Table 4). Cox
proportional hazards regressionwas used to compare the mortality
risk among patients with different statuses of SO. It indicated that
sarcopenia rather than SO tended to have a stronger impact on
mortality (Fig. 1).4. Discussion
Sarcopenic obesity, a conﬂuence of two common phenotypes of
aging-related changes in body composition, has gained extensive
research attention internationally. Sarcopenic obesity has been
associated with several adverse health outcomes, but the impact of
SO on mortality in the older population remains controversial.
Previous studies suggest that obesity may have a protective role
against mortality in older adults,22,23 but the protective effect may
be counteracted if obesity is combined with lowmuscle strength.27
Therefore, the unfavorable clinical outcomes of SO may have
resulted from sarcopenia with or without the coexistence of
obesity. In this study, patients were categorized into four groups in
accordance with their SO status, and comparisons between theolder and different statuses of sarcopenic obesity.
)
Sarcopenia (þ)
Central obesity () (N ¼ 276)
Sarcopenia (þ)
Central obesity (þ)
(N ¼ 134)
p
83.1  4.8 82.6  4.7 0.01
54.7 58.2 0.283
19.9 32.1 0.001
13.4 63.8 <0.001
22.2  2.7 26.6  2.5 <0.001
80.7  6.2 95.6  4.4 <0.001
13.1  7.8 13.5  8.2 <0.001
0.8  0.3 0.7  0.3 <0.001
134.2  22.2 140.6  20.3 0.004
70.7  13.8 71.8  13.0 0.589
103.0  29.6 110.4  34.8 0.001
174.6  36.8 174.1  33.8 0.033
111.7  53.0 141.9  89.9 <0.001
60.4  15.4 55.3  12.3 <0.001
28.3 23.9 <0.001
Table 4
Independent risk factors for mortality among older men aged 75 years and older.
Odds ratio 95% conﬁdence
interval
p
Sarcopenia (surrogated
by low handgrip strength)
2.64 1.687e4.135 <0.001
Age 1.08 0.929e1.007 0.108
Diabetes mellitus 1.70 1.083e2.667 0.021
Serum total cholesterol 1.00 0.999e1.010 0.130
Serum triglyceride 0.99 0.989e0.997 0.001
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muscle strength, and physical performance. A recent study
described sex-speciﬁc changes in body compositionwith relation to
frailty. It showed that physical frailty was associated with loss of
muscle mass in older men, but was attributed to fat percentage in
women.35 Compared to nonsarcopenic patients, sarcopenic pa-
tients with or without central obesity were more likely to die
during the study period. By contrast, sarcopenic nonobese patients
were at a signiﬁcantly higher risk of dying, compared to the SO
patients. Therefore, the results of this study supported the principle
that obesity in the elderly was protective against mortality and that
the protective effect may persist with sarcopenia. However, the
mortality risk of sarcopenia may outweigh the protective effect of
obesity among older men.
In this study, the prevalence of sarcopenia was as high as 60.3%,
and the prevalence of SO was 19.7%. Because of the lack of muscle
mass measurements, sarcopenia in this study was surrogated by
handgrip strength, as in other studies.33 The prevalence of sarco-
penia in this study was eventually compatible with a previous
report in this age group in which more than 50% of Hispanic and
non-Hispanic men over 80 years were sarcopenic.36 The mean age
of our study cohort was 82.5 years. Therefore, we assumed that the
adjusted cutoff of handgrip strength was satisfactory as the surro-
gate indicator of sarcopenia. Matching the proposed screening
cutoff of gait speed (0.8 m/second) in a European consensus, the
mean gait speed of sarcopenic patients in the current study was
0.7e0.8 m/second. The estimated prevalence of sarcopenia in this
study was comparable to data fromWesterners, although studies of
muscle mass measurement and its associative factors are still
needed because of the differences in ethnic backgrounds.37e39Fig. 1. Survival analysis of older people aged 75 years and older with different statuses
of sarcopenic obesity.Despite the extensive research effort, there are several limita-
tions in this study. First, the study participants were selected from
the Banciao Veterans Home (Taipei, Taiwan), a veterans retirement
community. All participants were males. The extrapolation of the
study results may be limited; however, the mortality risk of SO in
older adults internationally was unclear. Most previous studies
conﬁrmed the association between SO and mortality were limited
only to particular diseases.20,21 To the best of our knowledge, this is
the ﬁrst study evaluating the mortality impact of SO on the Chinese
population, which may broaden our understanding of SO in
different ethnic backgrounds. Second, because of the eligibility
criteria for the veterans home admissions, all participants were
homogenous in their demographic characteristics. However, ho-
mogeneity may help lessen confounding factors in data analysis
(e.g., social vulnerability) because the study participants were
universally low in their social engagement.30 Third, this study
lacked precise measurements of the study participants’ body
composition, including muscle mass and fat mass. However, as
previously stated, the adjusted cutoff for handgrip strength corre-
sponded favorably with gait speed. Therefore, we believe the
adjusted handgrip strength sufﬁciently surrogated the diagnosis of
sarcopenia.
In conclusion, sarcopenia was a highly prevalent condition
among older men living in a veterans home. During the 3-year
follow-up period, sarcopenia, but not sarcopenic obesity, signiﬁ-
cantly predicted all-cause mortality. The clinical signiﬁcance of
sarcopenic obesity should be reevaluated because sarcopenia per se
was a strong risk factor for mortality, whereas central obesity was
protective against it. The survival beneﬁts of obesitywere lost when
sarcopenia was present.
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